The acquisition adds capabilities to Evotec's drug discovery platform, including anti-infective screening, early PKPD (Pharmacokinetic/Pharmacodynamic) profiling, a range of disease and efficacy models for characterization of anti-bacterials, anti-fungals and anti-virals, StrainBank, a collection of clinical isolates, and core disease biology expertise in infection.
"Through the acquisition of Euprotec's capabilities and its disease biology know-how in infection, Evotec expands its technological portfolio to offer a complete infrastructure and discovery solutions in the field of infectious diseases," said Dr. Werner Lanthaler, chief executive officer of Evotec AG. "Importantly, we acquire highly innovative approaches, within our core competence along the discovery value chain, to open new therapeutic routes in the major market of infectious diseases. Currently, Evotec has two innovative programmes, TargetPicV and TargetPGB, to develop drugs to treat infectious diseases and with this acquisition we can expand this portfolio."
Dr. Lloyd Payne, chief executive officer and co-founder of Euprotec, added, "We are thrilled to be joining forces with Evotec and combining its leading-edge drug discovery platform with Euprotec's comprehensive infectious disease biology capabilities and expertise. We look forward to an exciting new phase of growth with Evotec, and, most importantly, working with our customers to accelerate the development of new breakthrough anti-infective vaccines and therapies."